596 related articles for article (PubMed ID: 33965591)
1. COVID-19 in a series of patients with aspirin-exacerbated respiratory disease.
White AA; Cahill KN; Jerschow E; Kuruvilla M; Sehanobish E; Bensko J; Laidlaw TM; Levy JM
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2900-2903. PubMed ID: 33965591
[No Abstract] [Full Text] [Related]
2. Multidisciplinary single-center outcomes compared to two-center outcomes for the treatment of aspirin exacerbated respiratory disease.
Bosso JV; Tripathi SH; Kennedy DW; Kohanski MA; Cohen NA; Palmer JN; Adappa ND
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2498-2500. PubMed ID: 33548515
[No Abstract] [Full Text] [Related]
3. A retrospective analysis of bronchiectasis in patients with aspirin-exacerbated respiratory disease.
Chen YS; Bensko JC; Laidlaw TM; Buchheit KM
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2799-2801. PubMed ID: 32330669
[No Abstract] [Full Text] [Related]
4. Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease.
Laidlaw TM; Gakpo DH; Bensko JC; Buchheit K
J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3170-3171. PubMed ID: 32739465
[No Abstract] [Full Text] [Related]
5. Co-treatment of non-steroidal anti-inflammatory drug-exacerbated respiratory disease with dupilumab and aspirin therapy after desensitization.
Buchheit KM; Hacker J; Maurer R; McGill A; Ryan T; Bensko JC; Laidlaw TM
Clin Exp Allergy; 2023 Sep; 53(9):974-977. PubMed ID: 37246613
[No Abstract] [Full Text] [Related]
6. Aspirin-exacerbated respiratory disease: personalized medical and surgical approaches.
Schlosser RJ
Int Forum Allergy Rhinol; 2020 Sep; 10(9):1035-1036. PubMed ID: 32634286
[No Abstract] [Full Text] [Related]
7. Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series.
Martin H; Barrett NA; Laidlaw T
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1384-1385. PubMed ID: 32956852
[No Abstract] [Full Text] [Related]
8. Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.
Patel P; Bensko JC; Bhattacharyya N; Laidlaw TM; Buchheit KM
Ann Allergy Asthma Immunol; 2022 Mar; 128(3):326-328. PubMed ID: 34863953
[No Abstract] [Full Text] [Related]
9. Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease.
Ghiasi Y; Wangberg H; Bagsic SRS; White A
Ann Allergy Asthma Immunol; 2022 Nov; 129(5):642-643. PubMed ID: 35908738
[No Abstract] [Full Text] [Related]
10. Aspirin-exacerbated respiratory disease: not always "adult-onset".
Tuttle KL; Schneider TR; Henrickson SE; Morris D; Abonia JP; Spergel JM; Laidlaw TM
J Allergy Clin Immunol Pract; 2016; 4(4):756-8. PubMed ID: 27393784
[No Abstract] [Full Text] [Related]
11. Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumab.
Bensko JC; McGill A; Palumbo M; Cahill KN; Laidlaw TM
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2466-2468. PubMed ID: 35643277
[No Abstract] [Full Text] [Related]
12. Aspirin-Exacerbated Respiratory Disease.
White AA; Stevenson DD
N Engl J Med; 2018 Sep; 379(11):1060-1070. PubMed ID: 30207919
[No Abstract] [Full Text] [Related]
13. Age as a factor in treatment of aspirin-exacerbated respiratory disease: relationship to required aspirin maintenance dose after desensitization.
Locke TB; Sweis AM; Gleeson PK; Lin TC; Civantos AM; Parhar HS; Corr AM; Kumar A; Salmon MK; Kohanski MA; Palmer JN; Bosso JV; Adappa ND
Int Forum Allergy Rhinol; 2020 Oct; 10(10):1180-1181. PubMed ID: 32761891
[No Abstract] [Full Text] [Related]
14. If aspirin-exacerbated respiratory disease treatment is a jigsaw puzzle, where do the aspirin and biologic pieces go?
White AA
Ann Allergy Asthma Immunol; 2022 May; 128(5):484-485. PubMed ID: 35489798
[No Abstract] [Full Text] [Related]
15. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
[No Abstract] [Full Text] [Related]
16. Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease.
Corey KB; Turner JH; Chowdhury NI; Chandra RK; Li P; Wu P; Cahill KN
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1644-1645.e1. PubMed ID: 35398556
[No Abstract] [Full Text] [Related]
17. [Aspirin-exacerbated respiratory disease: current diagnosis and treatment].
He SC; Xu YT
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Nov; 55(11):1091-1094. PubMed ID: 33210895
[TBL] [Abstract][Full Text] [Related]
18. Comparable safety of 2 aspirin desensitization protocols for aspirin exacerbated respiratory disease.
Pelletier T; Roizen G; Ren Z; Hudes G; Rosenstreich D; Jerschow E
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1319-1321. PubMed ID: 30144584
[No Abstract] [Full Text] [Related]
19. Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease.
Eid RC; Wudneh E; Zahid S; Cahill K; Jerschow E
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):102-104. PubMed ID: 31605753
[No Abstract] [Full Text] [Related]
20. Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
Taniguchi M; Mitsui C; Hayashi H; Ono E; Kajiwara K; Mita H; Watai K; Kamide Y; Fukutomi Y; Sekiya K; Higashi N
Allergol Int; 2019 Jul; 68(3):289-295. PubMed ID: 31235242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
